{
  "id": "1745402663161",
  "name": "csp documents",
  "description": "csp documents meta data",
  "metadataFields": [
    {
      "name": "Study Title",
      "description": "A randomized, double-blind, placebo-controlled clinical trial for evaluating XYZ drug."
    },
    {
      "name": "Protocol Number",
      "description": "Protocol ID used to uniquely identify this study in regulatory systems."
    },
    {
      "name": "Version Number",
      "description": "Document version to track protocol amendments."
    },
    {
      "name": "Date of Protocol Version",
      "description": "The official date of the current protocol version."
    },
    {
      "name": "Sponsor Name",
      "description": "The organization or entity sponsoring the clinical trial"
    },
    {
      "name": "IND/CTA Number (if applicable)",
      "description": "Investigational New Drug or Clinical Trial Application identifier"
    },
    {
      "name": "Study Acronym / Short Title",
      "description": "Abbreviated name used internally or in publications."
    },
    {
      "name": "Confidentiality Statement (Yes/No)",
      "description": "Indicates whether the document contains confidential content"
    },
    {
      "name": "Study Phase (I, II, III, IV)",
      "description": "The clinical phase of drug development this study belongs to."
    },
    {
      "name": "Study Type (Interventional, Observational, Registry)",
      "description": "Classification of the clinical study design"
    },
    {
      "name": "Study Design Description (Randomized, Double-Blind, Placebo-Controlled, etc.)",
      "description": "A structured outline of the trial methodology as described in the protocol"
    },
    {
      "name": "Number of Arms / Treatment Groups",
      "description": "Total number of intervention groups in the trial"
    },
    {
      "name": "Control Group Type (Placebo, Active Comparator, etc.)",
      "description": "Nature of the comparison group in the study"
    },
    {
      "name": "Blinding / Masking (Open-label, Single-blind, Double-blind)",
      "description": "The extent to which study participants and investigators are blinded to treatment assignment"
    },
    {
      "name": "Randomization (Yes/No)",
      "description": "Indicates if study participants were randomly assigned."
    },
    {
      "name": "Age Range",
      "description": "Minimum and maximum age criteria for study participation"
    },
    {
      "name": "Sex/Gender",
      "description": "Gender-based eligibility for study participants"
    },
    {
      "name": "Geographic Region",
      "description": "The global region(s) where the trial is being conducted"
    },
    {
      "name": "Country of Conduct",
      "description": "Specific country where the study is approved to run."
    },
    {
      "name": "Inclusion Criteria (list or reference section)",
      "description": "Eligibility criteria that participants must meet to enroll in the study"
    },
    {
      "name": "Exclusion Criteria (list or reference section)",
      "description": "Conditions or factors that disqualify potential participants from the study."
    },
    {
      "name": "Dose Level(s)",
      "description": "Prescribed dosage or treatment level used in the study"
    },
    {
      "name": "Route of Administration",
      "description": "he method by which the drug is administered (e.g., oral, IV)"
    }
  ]
}